Biswas, S., Srivastava, Y., Falodia, R., Hamadttu, A. (2026). Real-world effectiveness and safety of amivantamab plus chemotherapy versus chemotherapy alone in EGFR-mutant NSCLC after osimertinib: A propensity score–matched analysis.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.19_suppl.284